No Data
No Data
Jianfan Biotech (300529): 24Q1 performance improved drastically, fundamentals reversed, inflection point reached
Event: The company released its 2023 annual report and 2024 quarterly report. (1) 2023 Annual Report: In 2023, the company achieved operating income of 1.922 billion yuan, a year-on-year decrease of 22.84%; net profit to mother 4.36
Jianfan Biotech (300529): 1Q24's performance returned to rapid growth
The 1Q24 company has returned to a rapid development path and maintained that the “buy” rating company achieved revenue/net profit of 1.92 billion yuan (yoy -22.8%/-50.9%) in 23 years, which is lower than our expectations (estimated revenue)
Jianfan Biotech (300529): Channel inventory improved, performance resumed growth
Incident: The company released its 2023 annual report, achieving operating income of 1.92 billion yuan, a year-on-year decrease of 22.8%; realized net profit attributable to shareholders of the parent company of 400 million yuan, a year-on-year decrease of 50.9%; and realized net profit attributable to mother after deduction 4.
Jianfan Biotech (300529.SZ): Net profit of 285 million yuan in the first quarter increased by 44.90% year-on-year
Gelonghui, April 25, 丨 Jianfan Biotech (300529.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 744 million yuan, up 30.00% year on year; net profit attributable to shareholders of listed companies was 285 million yuan, up 44.90% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 271 million yuan, up 42.74% year on year; basic earnings per share were 0.3512 yuan.
Jianfan Biotech (300529): First-quarter results resumed high growth and domestic and foreign product development progressed smoothly
On April 25, 2024, the company released the 2023 Annual Report and the 2024 First Quarter Report. In 2023, the company achieved revenue of 1,922 million yuan, -23% year-on-year; net profit to mother of 436 million yuan
Jianfan Biology (300529): At the end of the journey of thorns, the road to prosperity can still be expected
Industry trends: Hemoperfusion is in line with the development trend of blood purification, and clinical superiority has been fully proven. Although the company's performance has fluctuated in recent years due to a series of external factors, we believe that its technology itself is advanced and in line with industry development
No Data